Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-term Investments (2016 - 2025)

United Therapeutics (UTHR) has disclosed Short-term Investments for 17 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 13.16% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, down 13.16% year-over-year, with the annual reading at $1.4 billion for FY2025, 13.16% down from the prior year.
  • Short-term Investments hit $1.4 billion in Q4 2025 for United Therapeutics, down from $1.4 billion in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.9 billion in Q4 2022 to a low of $899.0 million in Q1 2021.
  • Historically, Short-term Investments has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2022.
  • Biggest five-year swings in Short-term Investments: surged 81.24% in 2022 and later dropped 19.47% in 2025.
  • Year by year, Short-term Investments stood at $1.0 billion in 2021, then soared by 81.24% to $1.9 billion in 2022, then fell by 4.85% to $1.8 billion in 2023, then decreased by 12.12% to $1.6 billion in 2024, then decreased by 13.16% to $1.4 billion in 2025.
  • Business Quant data shows Short-term Investments for UTHR at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.5 billion in Q2 2025.